How big is Flora Growth Corp.?

As of Jun 18, Flora Growth Corp. has a market capitalization of 16.25 million and reported net sales of 53.27 million with a net profit of -13.30 million over the latest four quarters. Shareholder's funds were 4.51 million, and total assets were valued at 26.23 million.

As of Jun 18, Flora Growth Corp. has a market capitalization of 16.25 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 53.27 million for the latest four quarters. During the same period, Flora Growth Corp. experienced a net profit of -13.30 million.<BR><BR>As of Dec 24, the reporting period shows that the shareholder's funds amounted to 4.51 million, while total assets were valued at 26.23 million.

What does Flora Growth Corp. do?

Flora Growth Corp. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $12 million and a net loss of $1 million as of March 2025. It has a market cap of $16.25 million and key metrics indicating financial challenges, including a negative return on equity.

Overview: <BR>Flora Growth Corp. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 12 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -1 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 16.25 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.31 <BR>Return on Equity: -279.80% <BR>Price to Book: 3.42 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Should I buy, sell or hold Flora Growth Corp.?

Is Flora Growth Corp. overvalued or undervalued?

As of August 9, 2022, Flora Growth Corp. is rated as "risky" due to overvaluation indicated by a Price to Book Value of 3.04, a negative ROCE of -218.48%, and a year-to-date return of -35.85%, despite a recent positive stock return of 10.27%.

As of 9 August 2022, Flora Growth Corp. has moved from a grade of "does not qualify" to "risky." The company appears to be overvalued based on its current financial metrics. Key ratios include a Price to Book Value of 3.04, an EV to Sales ratio of 0.30, and a troubling ROCE of -218.48%. <BR><BR>In comparison to its peers, Flora Growth Corp. has a significantly negative EV to EBITDA ratio of -1.25, while Upexi, Inc. shows a worse EV to EBITDA of -37.9754, and ProPhase Labs, Inc. has a less negative EV to EBITDA of -1.6442. Despite a recent positive stock return of 10.27% over the past month compared to the S&P 500's 2.33%, the year-to-date return of -35.85% against the S&P's 12.22% indicates ongoing struggles for the company.

Is Flora Growth Corp. technically bullish or bearish?

As of September 11, 2025, Flora Growth Corp. shows a bullish trend with mixed technical signals, outperforming the S&P 500 recently but significantly underperforming year-to-date, indicating caution despite the overall bullish sentiment.

As of 11 September 2025, the technical trend for Flora Growth Corp. has changed from mildly bullish to bullish. The current stance is bullish, albeit with some mixed signals across different indicators. The MACD is mildly bullish on both weekly and monthly time frames, while the Dow Theory also supports a mildly bullish outlook in both periods. However, the moving averages indicate a mildly bearish trend on the daily chart, and the KST is bearish on both weekly and monthly time frames. The Bollinger Bands show a bullish signal weekly but are mildly bearish monthly. <BR><BR>In terms of performance, Flora Growth Corp. has outperformed the S&P 500 over the past week and month, with returns of 8.28% and 10.27% respectively, while it has significantly underperformed year-to-date and over the past year, with returns of -35.85% and -37.07%. Overall, the technical indicators suggest a bullish sentiment, but caution is warranted due to the mixed signals.